Akademik Veri Yönetim Sistemi
Eastern Journal of Medicine, cilt.29, sa.1, ss.7-13, 2024 (Scopus)
Antimuscarinic agents play an important function in the treatment of urinary incontinence. Intradetrussor onabotulinum toxin (Btx-A) injection is recommended if antimuscarinic drugs fail. This study examined Btx-A injection efficacy and adverse effects by age. The study has 54 patients who did not respond or tolerate two antimuscarinic drugs were injected with Btx-A. Before operation, urodynamics, voiding diary, International Consultation Incontinence Questionnaire Short-Form (ICIQ-SF) and Incontinence Quality of Life (I-QoL) were assessed. Six weeks after operation, these values were repeated. In light of these findings, the treatment effi cacy of the Btx-A injection was assessed. A two-way ANOVA test was performed for repeated measurements. The study included 54 patients, 37 female and 17 male. Twenty patients were 65 or older, 34 were under 65. Most patient group s benefited from Btx-A injections. Age doesn't affect Btx-A injection effectiveness. In 54 patients, maximal bladder capacity increased 50%, maximum detrusor pressure decreased 42%, incontinence quality of life score increased 71%, and average daily incontinence decreased 69%. Nine patients (16%) had urinary tract infections and one had urine retention (1.8%). IntradetrussorBtx-A injections should be favored due to their adequate efficacy and low incidence of side effects. Injection of intradetrussorBtx-A is a reliable, tolerable, reproducible, and effective invasive treatment for resistant urinary incontinence or overactive bladder. Considering the adverse effects of antimuscarinic agents in OAB patients 65 and older who are resistant, Btx-A injection should be recommended due to its low rate of complications and efficacy.